Omeros Corporation  

(Public, NASDAQ:OMER)   Watch this stock  
Find more results for Thomas E. Ray, III
+1.12 (10.03%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.93 - 12.31
52 week 10.48 - 30.23
Open 11.00
Vol / Avg. 0.00/1.31M
Mkt cap 465.62M
P/E     -
Div/yield     -
EPS -2.10
Shares 37.89M
Beta 1.43
Inst. own 66%
Nov 9, 2015
Q3 2015 Omeros Corp Earnings Release (Estimated) Add to calendar
Aug 11, 2015
Omeros Corp at Wedbush PacGrow Healthcare Conference
Aug 10, 2015
Q2 2015 Omeros Corp Earnings Call - Webcast
Aug 10, 2015
Q2 2015 Omeros Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -523.38% -13668.46%
Operating margin -501.00% -12988.50%
EBITD margin - -12928.01%
Return on average assets -100.19% -533.38%
Return on average equity -449.35% -
Employees 103 -
CDP Score - -


201 Elliott Ave W
SEATTLE, WA 98119-4240
United States - Map
+1-206-6765000 (Phone)
+1-206-6765005 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL), which is replacement surgery, to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform, which is for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline, which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor, drug targets and the other used to generate antibodies.

Officers and directors

Gregory A. Demopulos M.D. Chairman of the Board, President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Michael A. Jacobsen Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 56
Bio & Compensation  - Reuters
Marcia S. Kelbon J.D. Vice President - Patent, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Thomas J. Cable Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Peter A. Demopulos M.D. Director
Age: 61
Bio & Compensation  - Reuters
Ray Aspiri Independent Director
Age: 78
Bio & Compensation  - Reuters
Arnold C. Hanish Independent Director
Age: 67
Bio & Compensation  - Reuters
Leroy E. Hood M.D., Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters